Severe Aortic Stenosis and Coronary Artery Disease—Implications for Management in the Transcatheter Aortic Valve Replacement Era A Comprehensive Review by Goel, Sachin S. et al.
Journal of the American College of Cardiology Vol. 62, No. 1, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.096STATE-OF-THE-ART PAPERS
Severe Aortic Stenosis and Coronary Artery Diseased
Implications for Management in the Transcatheter
Aortic Valve Replacement Era
A Comprehensive Review
Sachin S. Goel, MD,* Mobolaji Ige, MD,y E. Murat Tuzcu, MD,* Stephen G. Ellis, MD,*
William J. Stewart, MD,* Lars G. Svensson, MD, PHD,z Bruce W. Lytle, MD,z Samir R. Kapadia, MD*
Cleveland, OhioMFrom the *Depart
Cleveland, Ohio; y
Cleveland, Ohio; a
Foundation, Cleve
tionships relevant
Manuscript receanagement of coronary artery disease (CAD) in patients with severe aortic stenosis (AS) referred for transcatheter
aortic valve replacement (TAVR) is posing challenges. Due to limited and heterogeneous data on the prevalence and
clinical impact of CAD on the outcomes of TAVR and the management strategies for CAD in patients undergoing
TAVR, we performed a comprehensive review of the literature. Signiﬁcant CAD is present in 40% to 75% of patients
undergoing TAVR. The impact of CAD on outcomes after TAVR remains understudied. Based on existing data, not all
patients require revascularization before TAVR. Percutaneous coronary intervention (PCI) should be considered for
severely stenotic lesions in proximal coronaries that subtend a large area of myocardium at risk. Ongoing studies
randomizing patients to surgical or percutaneous management strategies for severe AS will help provide valuable
data regarding the impact of CAD on TAVR outcomes, the role of PCI, and its timing in relation to TAVR. (J Am Coll
Cardiol 2013;62:1–10) ª 2013 by the American College of Cardiology FoundationRisk factors for aortic stenosis (AS) have been shown to be
similar to atherosclerosis (1). Consequently, coronary artery
disease (CAD) is often found concurrently in patients
presenting with severe symptomatic AS. The prevalence of
signiﬁcant CAD ranges from 25% to 50% in patients with
severe AS (2–5). Surgical aortic valve replacement (SAVR)
and concomitant coronary artery bypass grafting (CABG)
has been the standard management strategy for patients
with severe symptomatic AS and CAD (6). Recently,
transcatheter aortic valve replacement (TAVR) has emerged
as a less invasive and feasible treatment option in
patients at high risk for conventional SAVR (7,8). More
than 50,000 TAVRs have been performed around the
world to date; however, there is no consensus on the
management of severe CAD in this setting. We reviewed
the available published data to understand: 1) the prev-
alence of CAD in patients with severe AS; 2) clinical
impact of CAD on the outcomes of TAVR; and 3) the
management options for CAD in patients with severe
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CAD in SAVR patients. At the time of SAVR, the
prevalence of signiﬁcant CAD requiring concomitant
CABG has been shown to increase with age. Studies have
shown that in the age group of 61 to 70 years, 40% of
patients required concomitant CABG, whereas in patients
over the age of 80 years, >65% had concomitant CABG
(9,10). Several surgical databases have shown that CABG
increases operative and short-term mortality with SAVR
(11–14). Similarly, concomitant CABG appears to have an
adverse effect on long-term outcomes after SAVR (9,15).
However, there are no randomized controlled trials of
CABGþSAVR compared with SAVR alone in the presence
of signiﬁcant CAD. It is possible that the increase in short-
and long-term mortality in patients undergoing concomitant
CABG and SAVR compared with SAVR alone might be
a reﬂection of more severe and diffuse atherosclerosis in the
former group, which renders this population sicker and
direct comparisons with those undergoing SAVR difﬁcult to
interpret (16). In a study comparing the outcomes of SAVR
patients with severe AS and no CAD versus severe AS and
CAD where CABG was not performed, short- and long-
term outcomes were not found to be different (17). That
study, however, is notable for a small number of patients
(n ¼ 55) who did not undergo CABG with SAVR in
addition to most patients having single vessel CAD. In other
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2larger studies, leaving signiﬁcant
CADunrevascularized at the time
of SAVR was associated with
increased risk of adverse short-
and long-term outcomes (15,18).
Therefore, CABG is recom-
mended along with SAVR in the
presence of signiﬁcant CAD
(>50% to 70% stenosis) (6). This
includes bypassing moderately
severe lesions (i.e., 50% to 70%),
which might or might not be
clinically signiﬁcant.
Prevalence of CAD in TAVR
population. As shown in
Table 1, in concurrence with
SAVR published data, signiﬁcant
CAD is present in 40% to 75%
of patients undergoing TAVR
(7,8,19–34). In the FRANCE 2
(French Aortic National Cor-
eValve and Edwards 2) registry,
the largest published multicenter
study of 3,195 TAVR patients,
48% patients had CAD (33).Signiﬁcant numbers of patients undergoing TAVR also have
prior history of myocardial infarction (MI) (12% to 51%) and
prior percutaneous (16% to 34%) or surgical revascularization
(14% to 48%) (Table 1). Most of these studies have not re-
ported data on the burden of unrevascularized severe CAD
before undergoing TAVR. The only randomized TAVR
study, the PARTNER (Placement of AoRTic TraNs-
cathetER Valve) trial excluded patients with untreated clini-
cally signiﬁcant CAD requiring revascularization (7,8);
however, in the real world, patients being referred for TAVR
often have concomitant signiﬁcant CAD (35–37). Manage-
ment of concomitant signiﬁcant CAD in TAVR registries
and nonrandomized studies thus far has been variable and of
considerable emerging interest, raising issues around safety of
performing TAVR in patients with unrevascularized CAD
and also those related to performing percutaneous coronary
intervention (PCI) in patients with AS who will later need
TAVR, as discussed in the following.Impact of CAD on Outcomes of TAVR
Procedural and short-term outcome. Most patients with
signiﬁcant unrevascularized CAD were excluded from the
randomized PARTNER trial. Many patients undergoing
TAVR have previously undergone PCI on the most
signiﬁcant coronary lesions before TAVR. Nevertheless,
with the substantial selection criteria used in the currently
published data, Table 1 shows that the risk of procedural
death or death within 24 h post-TAVR is low. Second, as
shown in Table 1, the risk of MI within 30 days after TAVR
has ranged from 0% to 4.6%, except for a high rate of 15%described in the study by Svensson et al. (25), which was the
initial feasibility study of transapical TAVR. Of note, most
of these studies did not use a standardized deﬁnition for
MI, as recently suggested by the Valve Academic Research
Consortium (VARC) (38). There are signiﬁcant differences
in the threshold of peri-procedural cardiac biomarker ele-
vation for the diagnosis of MI in these studies. For example,
in the feasibility study by Svensson et al., MI was deﬁned as
development of new Q waves in 2 or more contiguous leads
with creatine kinase (CK) or CK-myocardial band (MB)
levels elevated above normal, and non–Q-wave MI was
deﬁned as CK elevation to twice normal (25). From a sub-
sequent study by Rodes-Cabau et al. (39), it is now known
that even patients without CAD undergoing TAVR have
some elevation in cardiac biomarkers; hence a modest
elevation of CK or CK-MB above normal range should not
be used to deﬁne a coronary-related MI. It is hoped that
with VARC deﬁnitions, all post-TAVR endpoints will be
standardized, leading to easier interpretation and compar-
ison of outcomes in future TAVR studies.
Long-term outcome. Few studies have directly evaluated
and reported the impact of CAD on outcomes of patients
after TAVR (Table 2) (40–46). Dewey et al. (40) were the
ﬁrst to report the impact of CAD as deﬁned by prior CABG
or prior PCI in 171 patients undergoing TAVR. In that
study, patients with CAD had higher 30-day (13.1% vs.
1.2%, p ¼ 0.002) and 1-year mortality (35.7% vs. 18.4%,
p ¼ 0.01) compared with patients without CAD. Patients
with CAD were 10 times more likely to die within 30 days
after TAVR compared with those without CAD (95%
conﬁdence interval: 2.1 to 174.8) (40). Lack of data on the
degree of CAD and its physiological burden were the main
limitations of this study. In contrast, a study by Masson et al.
(41) evaluated the impact of CAD on outcomes of TAVR
stratiﬁed by the extent of CAD, as characterized by the
Duke Myocardial Jeopardy Score (DMJS). The DMJS is
a well-validated prognostic marker in patients with CAD
that takes into account the area of myocardium at risk and is
more accurate at prediction of outcomes compared with the
number of diseased coronary arteries (47). In contrast to the
study by Dewey et al. (40), the study by Masson et al. (41)
did not ﬁnd a statistically signiﬁcant difference in the 30-day
mortality post-TAVR in patients with CAD compared with
those without CAD (11.5% vs. 6.3%). However, given the
almost 2-fold higher risk, it is possible that these results
would have been signiﬁcant in a larger number of patients.
The other notable ﬁnding in that study is that 15 of 136
patients (11%) underwent PCI before TAVR, which
reduced the DMJS by a median of 2 points (41). A recent
study by Gautier et al. (42) also evaluated the impact of
CAD on the outcomes of TAVR in 145 patients. They
found no difference in the outcomes of 30-day or 1-year
post-TAVR mortality in patients with and without CAD.
Again, similar to the study by Masson et al. (41), 11 of 83
patients with CAD (17%) in their study underwent PCI
before TAVR. This was mainly clinically driven on the basis
Table 1 Prevalence of CAD and Outcomes in Major Published TAVR Studies
First Author (Ref. #)
Prevalence of CAD Outcomes
CAD
Prior
MI
Prior
CABG
Prior
PCI
Procedural/24-H
Death
30-Day/
In-HospitalMI 1-Yr MI
30-Day/
In-HospitalDeath
1-Yr
Death
Leon et al. (7)
n ¼ 179
67.6% 18.6% 37.4% 30.5% 1.1% 0 0.6% 4.5%*
5.0%
19.6%*
30.7%
Eltchaninoff et al. (19)
n ¼ 244
41.3% 22.5% 25.4% 0.4% 12.7%
Rodes-Cabau et al. (20)
n ¼ 339
69.0% 51.0% 34.2% 29.2% 1.7% 1.2% 10.4%
Thomas et al. (21)
n ¼ 1,038
51.9% 22.6% 1.4% 8.5% 23.9%
Himbert et al. (22)
n ¼ 75
61.0% 20.0% 31.0% 22.0% 4.0% 9.0%*
10.0%
22.0%
Lefevre et al. (23)
n ¼ 130
60.0% 20.8% 31.5% 24.6% 0.8% 4.6%
0.8%y
6.9%
0.8%y
13.8% 36.9%
Walther et al. (24)
n ¼ 168
49.0% 18.0% 14.0% 16.0% 1.0% 4.0% 15.0% 37.0%
Svensson et al. (25)
n ¼ 40
27.5% 47.5% 45.0% 7.5% 15.0% 17.5%
Grube et al. (26)
n ¼ 136
59.5% 25.7% 30.1% 2.2% 2.2% 2.2% 12.5% 18.4%
Petronio et al. (27)
n ¼ 514
50.4% 22.0% 16.3% 29.0% 0.8% 0.6% 5.4%
Piazza et al. (28)
n ¼ 646
56.8% 11.9% 20.1% 28.9% 1.7%* 0.6% 5.8%*
8.0%
Zahn et al. (29)
n ¼ 697
60.2% 20.6% 34.2% 12.4%
Smith et al. (8)
n ¼ 348
74.9% 26.8% 42.6% 34.0% 0.9% 0 0.4% 3.4%
3.2%*
24.2%
14.3%*
Moat et al. (31)
n ¼ 870
47.6% 1.3% 7.1% 21.4%
Tamburino et al. (30)
n ¼ 663
48.3% 21.6% 15.7% 28.5% 0.9% 1.2% 5.9% 15.0%
Wenaweser et al. (32)
n ¼ 257
18.3% 21.0% 22.6% 0.4% 1.6% 6.6% 17.1%
Gilard et al. (33)
n ¼ 3,195
48.0% 16.0% 18.0% 9.7% 24.0%
Beckman et al. (34)
n ¼ 3,875
55.0% 5.1% 7.7%
*Cardiovascular; ycoronary obstruction.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TAVR ¼ transcatheter aortic valve replacement.
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3of angina and/or severe ostial or proximal coronary stenoses
subtending a large area of myocardium at risk (5 of 11
patients had proximal left anterior descending coronary
artery stenosis). In this study, 16 of 83 (19%) patients in the
CAD group were free of residual signiﬁcant coronary
stenosis (42). The recently published U.K. TAVI (United
Kingdom Transcatheter Aortic Valve Implantation) registry
had a 14% rate of PCI (55 of 410 patients) in patients
undergoing TAVR (31), similar to the rates of PCI in the
TAVR studies by Masson et al. (1) and Gautier et al. (42).
In another study reporting outcomes of TAVR in 256
patients, Wenaweser et al. (43) compared the outcomes of
59 patients with signiﬁcant CAD and a mean DMJS of 5.0,
who underwent PCI (23%) before TAVR, with 197 patients
who did not undergo PCI (mean DMJS 1.2) before TAVR.
They found, although of marginal statistical signiﬁcance,
a 2-fold higher risk of 30-day post-TAVR mortality in
patients who underwent PCI before TAVR compared withthose who had TAVR alone (10.2% vs. 5.2%, p ¼ 0.24).
These ﬁndings raise concerns about the adverse impact of
CAD on outcomes of TAVR, similar to surgical published
data as discussed in the preceding text, although they do not
advise on whether to revascularize by PCI before TAVR. It
can be summarized that a select group of patients with
CAD, ranging from 11% to 23%, have undergone PCI
before TAVR (31,41–43), although it is not conclusive
about how and when that should be performed.
Cause of death post-TAVR. In the inoperable cohort of
the PARTNER trial, the 1-year mortality in the TAVR arm
was 30.7% versus 49.7% in the standard medical therapy arm
(7). There were a total of 71 deaths at 1 year in the TAVR
arm, of which 27 (38%) were classiﬁed as cardiovascular
death, 27 (38%) were non-cardiovascular and in 17 (24%)
the cause of death was unknown. Similarly, in the SOURCE
(Edwards SAPIENAortic Bioprosthesis EuropeanOutcome)
registry, of the 179 deaths between 30 days and 1 year, 45
Table 2 Impact of CAD on TAVR Outcomes
First Author (Ref. #) CAD Deﬁnition
STS, Log
EuroScore
30-Day
Mortality
1-Yr or Follow-Up
Mortality Conclusions
Dewey et al. (40)
(n ¼ 171)
Prior CABG or PCI CAD patients had increased risk of
30-day mortality, OR: 10.1
(95% CI: 2.1–174.8, p ¼ 0.009)
and overall mortality, OR: 20.3
(95% CI: 2.4–172.3, p ¼ 0.006)
CAD, 84 (49%) 14.5, 36.6 13.1% 35.7%
No CAD, 87 (51%) 9.9, 27.5 1.2% 18.4%
Masson et al. (41)
(n ¼ 136)
DMJS, 50%
stenosis
14% 22.1% No risk of increased 30-day
mortality (p ¼ 0.56) or 1-yr
mortality (p ¼ 0.63) in patients
with CAD and without CAD
DMJS
0, No CAD, 32 (23%) 7.1, 21.5 6.3% 18.8%
0, CAD, 41 (30%) 9.4, 25.0 28.8%
2, 28 (21%) 9.0, 33.5 35.7%
4, 18 (13%) 9.7, 32.5 11.1%
6–12, 17 (13%) 11.3, 40.0 29.4%
15 of 136 (11%) patients
underwent PCI before TAVR
Gautier et al. (42)
(n ¼ 145)
Prior MI, CABG, PCI
or 70% stenosis
(50% for LMT)
No risk of increased 30-day
mortality (p ¼ 0.37) or 1-yr
mortality (p ¼ 0.28) in patients
with and without CADCAD, 83 (57%) NA, 29 10% 24.0%
No CAD, 62 (43%) NA, 24 15% 29.0%
PCI was performed in 11 of
83 (17%) patients before TAVR
Wenaweser et al. (43)
(n ¼ 256)
DMJS, SYNTAX score No risk of increased 30-day
mortality in patients undergoing
TAVR alone (55% with CAD)
compared with those undergoing
revascularization with PCI
followed by TAVR
PCI þ TAVR, 59 (23%)
(Mean DMJS 5.0)
7.6, 28.6 10.2%
TAVR alone, 197 (77%)
(Mean DMJS 1.2)
6.1, 24.2 5.6%
(p ¼ 0.24)
Khawaja et al. (45)
(n ¼ 164)
70% stenosis CAD patients had increased 30-day
and 12-month mortality, OR: 2.92
(95% CI: 1.34–6.35, p ¼ 0.007)CAD, 54 (33%) (50% for LMT) on
pre-TAVR LHC
NA, 23.5 16.7% 31.5%
No CAD, 110 (67%) NA, 21.4 3.8% 14.4%
10 of 54 (19%)
patients underwent PCI
before TAVR
(p ¼ 0.005) (p ¼ 0.01)
Ussia et al. (44)
(n ¼ 659)
No risk of increased 1-yr
mortality in patients with and
without CAD, adjusted HR: 0.74
(95% CI: 0.40–1.36, p ¼ 0.3)
CAD, 251 (38%) Prior PCI or CABG NA, 28.6 6% 14.5%
No CAD, 303 (62%) NA, 21.4 5.9% 15.9%
Wendler (46)
(n ¼ 2,307)
Prior CABG No risk of increased mortality in
patients with and without history
of prior CABGCABG þ 502 (22%) NA, 35.2 10.2% 23.5%
CABG 1,805 (78%) NA, 23.6 9.3% 23.5%
Values are n (%), unless otherwise indicated.
CI ¼ conﬁdence interval; DMJS ¼ Duke Myocardial Jeopardy Score; EuroScore ¼ European System for Cardiac Operative Risk Evaluation; HR ¼ hazard ratio; LHC ¼ left heart catheterization; LMT ¼ left
main trunk; OR ¼ odds ratio; STS ¼ Society of Thoracic Surgeons; other abbreviations as in Table 1.
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4(25%) were cardiac, 88 (49%) were noncardiac, and in 46
(26%) patients the cause of death was unknown (21). Among
the deaths of unknown cause in the SOURCE registry, 18
(39%) were classiﬁed as sudden death, which according to the
new VARC deﬁnitions would be classiﬁed as cardiac deaths
(48). In fact, the authors of the SOURCE registry note that
a number of these patients were actually “found dead in bed”
(21). It remains to be seen whether, in addition to the proce-
dural and in-hospital outcomes, revascularization of signiﬁcant
CADwill have an impact on the long-term outcomes of thesehigh-risk patients undergoing TAVRwho have a very high 1-
year risk of cardiovascular mortality, as noted in the
PARTNER trial and SOURCE registry.
Difﬁculties in Interpreting Outcome Data in
Patients With CAD Undergoing TAVR
As noted in the preceding text and in Table 2, studies
comparing outcomes of TAVR in patients with and without
CAD have used different deﬁnitions for CAD, there is
JACC Vol. 62, No. 1, 2013 Goel et al.
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5signiﬁcant heterogeneity with regard to data on the anatomic
and physiological burden of CAD, and a variable number of
patients (11% to 23%) have already undergone PCI before
TAVR on the basis of clinical evaluation by the managing
team of physicians and the area of myocardium felt to be at
risk. These factors make it difﬁcult to interpret the direct
impact of CAD on the short- and long-term outcomes of
TAVR. Future studies should clearly deﬁne the coronary
characteristics of patients in terms not only of anatomy on
the pre-TAVR coronary angiogram and the number of
unrevascularized coronary territories but also of an assess-
ment of the physiological burden in some form, such as the
DMJS. There are limited data directly comparing TAVR
with SAVR, the concomitant CAD management strategies,
and the completeness of revascularization with each
approach. In a recently published study, Wenaweser et al.
(32) compared the outcomes of patients with severe AS
according to whether they underwent SAVR, TAVR, or
medical therapy. They found that 44% of patients with
severe AS and CAD who underwent SAVR had concomi-
tant total coronary revascularization by CABG, whereas only
23% of patients with severe AS and CAD who underwent
TAVR had total revascularization by PCI. This is partly
because all coronary lesions 50% are bypassed at the time
of SAVR; however, with PCI, the indication for revascu-
larization tends to be more conservative and performed
when the stenosis exceeds 70% or functional ischemia is
more certain. Future randomized studies of SAVR and
TAVR that include data on completeness of revasculariza-
tion should help guide selection of patients for percutaneous
revascularization before TAVR.
Management Options for CAD in Patients With
Severe AS Being Considered for TAVR
The following considerations arise when evaluating patients
with severe AS and CAD for TAVR: 1) hemodynamic
alterations during TAVR in presence of unrevascularized
CAD; 2) need for revascularization; 3) mode of revascular-
izationdPCI or surgical; 4) safety of performing PCI in
patients with severe AS; 5) timing of PCI in relation to
TAVR; and 6) type of stent and management of antiplatelet
regimen.
One of the procedural concerns during TAVR is the risk
of inducing ischemia and hemodynamic instability in
patients with signiﬁcant unrevascularized CAD, especially
during rapid ventricular pacing and balloon inﬂation, which
are both part of the TAVR procedure. This real risk of this
potential problem is unknown. In the Multicenter Canadian
TAVR study, Rodes-Cabau et al. (20) showed that need for
hemodynamic support during TAVR with intra-aortic
balloon counter-pulsation or extracorporeal circulation due
to severe sustained hypotension or hemodynamic collapse
was an independent predictor of early as well as late
mortality after TAVR. Even though it is unproven, intui-
tively this risk might potentially be higher in patients withunrevascularized severe CAD. As brieﬂy mentioned in the
preceding text, in the study evaluating the incidence and
prognostic value of myocardial injury in the form of cardiac
enzymes after TAVR, the same group showed that elevated
CK-MB and troponin levels post-TAVR were associated
with less improvement in left ventricular ejection fraction
(EF) and higher cardiac mortality at follow-up (39).
However, they did not ﬁnd the presence of CAD or the
presence of unrevascularized CAD to be a predictor of
elevated cardiac enzymes post-TAVR (39). Transapical
TAVR and baseline renal dysfunction were found to be
predictive of greater increase in cardiac biomarkers post-
TAVR in that study. These ﬁndings suggest that not all
patients with signiﬁcant CAD require revascularization
before TAVR, in concurrence with the current clinical
practice in the aforementioned TAVR studies (31,41–43).
Pending randomized studies addressing this issue, it is likely
that the patients most likely to derive beneﬁt from PCI
before or with TAVR are those with a large area of
myocardium at risk, such as that subtended by a severe ostial
or proximal stenosis in a large epicardial coronary artery.
Fractional ﬂow reserve–guided PCI has been shown to be
beneﬁcial compared with conventional angiography-guided
PCI in patients with multivessel CAD, without signiﬁcant
valve disease (49). Similarly, fractional ﬂow reserve might
have a role in assessing hemodynamic signiﬁcance of coro-
nary stenoses during pre-TAVR coronary angiography and
guiding revascularization; however, this has not been vali-
dated in patients with severe AS.
Mode of revascularization: percutaneous or surgical. In
patients with severe left main disease or 3-vessel CAD,
particularly in those with diabetes mellitus, outcomes after
CABG have been shown to be superior to PCI (50,51).
Patients with severe symptomatic AS with severe multivessel
CAD or left main disease, who are at low or intermediate
risk for surgery, should be considered for CABG and SAVR
instead of percutaneous approach for treating both severe AS
and CAD.
Safety of PCI in patients with severe AS. Historically,
PCI has not been performed commonly in patients with
severe AS. Therefore the outcomes of PCI in patients with
severe AS have remained under-studied (52,53). Occasion-
ally, patients with severe AS undergo PCIdsuch as those at
high risk of morbidity and mortality from SAVR or those
with temporary contraindications for SAVR, such as acute
coronary syndromes or when symptoms are felt to be mainly
from CAD. We recently published our experience with PCI
in 254 patients with severe AS over an 11-year period,
comparing the short-term outcomes after PCI with a
propensity-matched group of 508 patients without AS who
underwent PCI during the same time period (54). We found
no difference in the risk of procedural complications or 30-
day post-PCI mortality in patients with severe AS and the
propensity-matched control subjects (4.3% vs. 4.7%, hazard
ratio: 0.93, 95% conﬁdence interval: 0.51 to 1.69, p ¼ 0.2).
However, patients with severe AS and EF 30% and those
Goel et al. JACC Vol. 62, No. 1, 2013
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6with Society of Thoracic Surgeons (STS) score 10% were
found to be at the highest risk of 30-day mortality after PCI
(15.4% and 10.4%, respectively) in our study, whereas
mortality risk was low in patients with EF >30% and those
with STS score <10 (1.2% and 0%, respectively). Progressive
cardiac and multi-organ failure was the cause of death in 9 of
11 (82%) patients with severe AS who died within 30 days
after PCI. The ﬁndings of our study indicate that PCI can be
performed in patients with severe AS without an increased
risk of short-term mortality compared with a propensity-
matched population with signiﬁcant CAD but without AS.
Nevertheless, a 30-day post-PCI mortality of 4.3% is
a sobering ﬁnding, and patients with severe AS should be
considered a high-risk group when being considered for PCI.
This underscores the importance of patient selection for PCI
before TAVR and weighing the risks and beneﬁts of per-
forming PCI before TAVR versus performing TAVR in the
presence of unrevascularized signiﬁcant CAD. There might
also be a role for balloon aortic valvuloplasty, particularly if
TAVR is not possible or feasible in a timely fashion after
PCI, because most deaths in the 30 days after PCI in our
study were related to progressive cardiac and multi-organ
failure, which is likely an outcome of untreated severe
symptomatic AS. Because patients with left ventricular
EF30% and STS score10% were at a high risk of 30-day
mortality after PCI in our study, balloon aortic valvuloplasty
might have a role in these patients either as a staged proce-
dure or concomitantly with PCI, although the available data
are limited with these approaches (55,56).
Timing of revascularization of severe CAD in patients
with severe AS undergoing TAVR. As stated in the
preceding text, there are 2 key questions in the management
of high-risk patients with severe AS and concomitant
signiﬁcant CAD. First, is the CAD signiﬁcant enough to
warrant an intervention? Second, if a PCI is deemed
necessary, what is the best timing for PCI? It is still unclear
which patients should undergo PCI before TAVR.
However, it is logical, partly on the basis of the aforemen-
tioned studies, that severe coronary lesions that subtend
a large area of myocardium such as proximal epicardial
lesions should be considered for PCI before TAVR. The
PCI can be performed before TAVR or concomitantly as
a single-stage procedure with TAVR or be staged after
TAVR. There are pros and cons to consider with each
approach. Studies reporting outcomes of PCI before or
concomitantly with TAVR are summarized in Table 3.
PCI before TAVR. The potential advantages of this
approach are: 1) simpliﬁed access to the coronaries before
TAVR; 2) less risk of ischemia and hemodynamic instability
during rapid pacing and balloon inﬂation during subsequent
TAVR; and 3) minimizing the contrast load by giving it
at 2 separate points in time, thus minimizing the risk of
contrast nephropathy. There are 2 potential issues with this
approach: 1) dual antiplatelet therapy after PCI and its
impact on bleeding outcomes after subsequent TAVR,
especially via non-transfemoral approach; and 2) the safety ofperforming PCI in the presence of severe AS. As discussed
earlier, we found that PCI can be performed without an
increased risk of short-term mortality in patients with severe
symptomatic AS, compared with a propensity-matched
group of patients without AS (54). In concurrence with
our ﬁndings with regard to safety of PCI in patients with
severe AS, Abdel-Wahab et al. (57) found that PCI before
TAVR in 55 patients (median duration between PCI and
TAVR was 10 days) was not associated with worse 30-day
(Fig. 1) and 6-month outcomes compared with 70 patients
undergoing TAVR alone. Nevertheless, one has to be careful
while selecting patients with severe AS for PCI before
TAVR, because we found a high 30-day post-PCI mortality
in patients with severe AS and low EF (<30%) and those
with a high STS score (>10). Even though there was no risk
of increased bleeding between the 2 groups in the study by
Abdel-Wahab, this deserves further study, especially because
previous data by Byrne et al. (58) suggest that PCI followed
by valve surgery (median duration 10 days) is associated with
a signiﬁcantly increased risk of bleeding. A hybrid procedure
where PCI is performed immediately before minimally
invasive SAVR is also being proposed; however, the risk of
postoperative bleeding with dual antiplatelet agents merits
further evaluation.
PCI with TAVR as combined procedure. Some groups
have proposed performing PCI on the most signiﬁcant
coronary lesions at the time of TAVR as a single staged
procedure (59). Pasic et al. (60) reported their experience
with this approach in 46 of 419 (11%) patients undergoing
TAVR. They performed PCI on signiﬁcant coronary lesions
that subtended a large area of myocardium, such as proxi-
mal or mid left anterior descending coronary artery
stenosis 90%, proximal or mid stenosis 90% in dominant
right coronary artery or left circumﬂex coronary artery, or left
main trunk stenosis 50%. There were 2 deaths (4.3%)
within 30 days post-PCIþTAVR in this studyd1 patient
died after developing severe transvalvular regurgitation, and
the other died after re-thoracotomy due to hematoma in the
pleural space followed by multi-organ failure. Technical
success was achieved in all patients in this study. The authors
concluded that combined PCI and TAVR procedure is safe
and feasible, and they suggest this approach in all patients
when PCI is felt necessary. The limitation of this study is
that there was no control arm consisting of patients
undergoing isolated TAVR or staged PCI followed by
TAVR. The potential advantages of this combined approach
are: 1) treatment of both pathologies at the same time with
elimination of potential morbidity and mortality after PCI
while awaiting deﬁnitive management (i.e., TAVR for
severe AS); 2) 1 arterial access for PCI and TAVR on the
same day, with potential reduction in the risk of vascular
access site complications and bleeding; and 3) possible
reduction in the risk of inducing ischemia and hemodynamic
instability while performing TAVRdthis might be true if
PCI is performed just before TAVR. This was not the case,
however, in the study by Pasic et al.dthey recommend
Table 3 PCI Staged or Combined With TAVR
First Author (Ref. #) PCI Criteria
STS, Log
EuroScore
30-Day
Mortality
Follow-Up
Mortality Conclusions
Abdel-Wahab et al. (57)
(n ¼ 125)
All major vessels 50%
stenosis
6 months PCI before TAVR is not
associated with worse
30-day or 6-month outcomesPCI þ TAVR, 55 (44%) NA, 25.1 2.0% 9.0%
TAVR alone, 70 (54%) NA, 23.6 6.0% 14.0%
52 had PCI before TAVR,
3 had single stage PCIþTAVR
p ¼ 0.27 p ¼ 0.42
Pasic et al. (60)
(n ¼ 419)
LMT >50%
90% prox/mid LAD,
RCA, LCX
Months
12 12.9%
24 30.3%
Combined TAVRþPCI is safe
and feasible
TAVRþPCI, 46 (11%) 23, 40 4.3% 36 30.3%
Wenaweser et al. (43)
(n ¼ 256)
PCI is safe in TAVR patients
as staged or concomitant
procedureStaged PCI þTAVR, 23 (9%) DMJS, SYNTAX score 8.2, 30.3
PCIþTAVR, 36 (14%) 7.3, 24.5
TAVR alone, 197 (77%) 6.1, 24.2 5.6%
p ¼ 0.24
Conradi et al. (61)
(n ¼ 179)
Staged PCI or concomitant
PCI and TAVR feasible.
Higher risk of renal failure
in concomitant approach
Staged PCIþTAVR, 21 (12%)
PCIþTAVR, 7 (4%)
Values are n (%), unless otherwise indicated.
LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary artery; prox ¼ proximal; RCA ¼ right coronary artery; other abbreviations as in Tables 1 and 2.
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7performing TAVR ﬁrst followed by PCI during the same
procedure. Their rationale is that severe AS is the main
lesion, and treating it ﬁrst can potentially improve
myocardial perfusion to a certain extent, even in the pres-
ence of a signiﬁcant coronary stenosis. With this combined
approach there is also a potential increased risk of contrast
nephropathy secondary to the additional dye load during
the same procedure. Wenaweser et al. (43) performedFigure 1 Staged or Combined PCI With TAVR
30-day mortality in published studies (43,57,60,61) including patients undergoing
staged or combined percutaneous coronary intervention (PCI) with transcatheter
aortic valve replacement (TAVR).concomitant PCIþTAVR by performing PCI ﬁrst, fol-
lowed by TAVR in the same session, in contrast to the
approach of Pasic et al. They also compared outcomes
between patients undergoing concomitant PCI and TAVR
versus those undergoing staged PCI followed by TAVR
(after a mean of 34 days) (Fig. 1) (43). In that study, there
was a statistically nonsigniﬁcant trend toward higher inci-
dence of major access-related complication and life-
threatening bleeding in the staged PCI and TAVR group
compared with the concomitant PCI and TAVR group. In
a study by Conradi et al. (61), there was a higher risk of
renal failure in patients undergoing concomitant PCI and
TAVR. Future studies evaluating the merits and demerits
of both these approaches are required.
PCI after TAVR. There are a few case reports on PCI after
TAVR; however, this approach is of some concern due to
access issues (62,63). The valve struts could interfere with
cannulation of coronaries, and catheter manipulation could
potentially even dislodge the valve, although this is unlikely.
As the TAVR experience continues to grow, ongoing
studies will shed more light on whether PCI after TAVR
might be a safe and feasible option in cases where the need
for coronary revascularization arises post-TAVR.
Type of stentddrug-eluting or bare-metaldand interval
between PCI and TAVR. In the absence of large-scale
studies evaluating the outcomes of drug-eluting stent
(DES) versus bare-metal stent in patients undergoing
TAVR, this decision should be made on an individual basis
Goel et al. JACC Vol. 62, No. 1, 2013
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8by the heart team, depending upon the perceived risk of
bleeding and restenosis of the patient. For example, in
patients with atrial ﬁbrillation, the risk of bleeding with
warfarin and long-term dual antiplatelet therapy should be
weighed against the risk of restenosis with bare-metal stent.
For other patients, DES might be suitable. The other issue
relates to the time interval between PCI and TAVR. The
ideal interval remains undeﬁned and again should be indi-
vidualized on the basis of the speciﬁc clinical situation. Dual
antiplatelet therapy in patients with DES is not an issue in
case of transfemoral TAVR. However, it has implications
for patients being randomized to the SAVR arm in future
studies or non-transfemoral TAVR where patients are
placed in the studies after DES has already been implanted.
Such patients with recent (<6 months) DES implantation
should be excluded from randomization unless SAVR or
TAVR (in case of non-transfemoral access) can be per-
formed without interruption of dual antiplatelet therapy.
Future Directions
The ongoing ACTIVATION trial (Percutaneous coronary
intervention prior to transcatheter aortic valve implantation:
a randomized controlled trial), which is randomizing
patients with CAD to pre-TAVR PCI and no pre-TAVR
PCI, will help answer the question of whether pre-TAVR
PCI has favorable impact on outcomes after TAVR. Other
ongoing randomized trials such as SURTAVI (Surgical
Replacement and Transcatheter Aortic Valve Implantation)
and PARTNER II are including patients with severe AS
and signiﬁcant CAD requiring revascularization. The
SURTAVI trial is designed to compare TAVR with the
CoreValve system (Medtronic, Minneapolis, Minnesota)
with SAVR in intermediate risk patients (STS risk score 4
to 10). Similarly, the PARTNER II trial has been
designed to compare TAVR with the Edwards Sapien XT
valve (Edwards Lifesciences, Irvine, California) with SAVR
in intermediate-risk (STS score 4 and higher) patients. In
both these ongoing randomized TAVR studies, patients
with concomitant severe CAD will be randomized for per-
cutaneous or surgical treatments. It is important to note that
management strategies (i.e., TAVRwith orwithout PCI) will
be compared with SAVR with or without CABG. These
are not trials to compare the PCI with CABG, but they
are trials to compare percutaneous strategy for the treat-
ment of AS and CAD with surgical strategies. The deci-
sions with regard to targets for revascularization are deﬁned
before randomization for each strategy. Revascularization
before randomization in the study will be discouraged
unless patients present with acute coronary syndrome
(non–ST-segment elevation MI or ST-segment elevation
MI) requiring urgent PCI. Such patients can still be
randomized to SAVR or TAVR arm depending on stent
type and required duration of dual antiplatelet therapy. The
need for revascularization in stable CAD patients will be
determined by the heart team on an individual basis.Aforementioned factors with regard to DES use will need
to be considered while considering elective PCI. Complex
CAD such as unprotected left main trunk and multivessel
CAD with SYNTAX score 33 will be excluded in both
trials. Completeness of revascularization might differ in the
2 arms. For example, a chronic total occlusion of a well-
collateralized right coronary artery will likely be left alone
in the TAVR arm; however, a bypass graft if feasible
during SAVR will be performed. Data from ongoing
studies should provide valuable information with regard to
the impact of CAD on TAVR outcomes and the role of
revascularization with PCI and its timing in patients
undergoing TAVR.
Conclusions
Signiﬁcant CAD is commonly encountered in patients with
severe symptomatic AS being evaluated for TAVR. The
impact of CAD on short- and long-term outcome after
TAVR remains understudied and should be rigorously
evaluated in future studies. As experience with TAVR
evolves, evidence-based management strategies for patients
with severe AS and CAD will guide clinicians taking care of
these high-risk patients. Revascularization should be con-
sidered for severe coronary stenoses in proximal epicardial
coronary vessels that subtend a large area of myocardium
at risk. A PCI can be safely performed in patients with
severe AS without an increased risk of short-term adverse
outcomes, particularly in those with preserved left ventricular
function. Patients should undergo TAVR without a long
delay after PCI. The choice of stents and the time interval
between PCI and TAVR should be individualized. Patients
with complex coronary disease involving major coronary
arteries, especially in diabetic patients, should be considered
for surgical revascularization and SAVR when appropriate.
The concept of “heart team” in decision making, including
those related to coronary revascularization, is critical in
optimizing TAVR outcomes.
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